CN102631396B - Anti-lung cancer alstonia-leaf traditional Chinese herbal composite, method for preparing same and application thereof in preparing anti-lung cancer medicine - Google Patents
Anti-lung cancer alstonia-leaf traditional Chinese herbal composite, method for preparing same and application thereof in preparing anti-lung cancer medicine Download PDFInfo
- Publication number
- CN102631396B CN102631396B CN2012101417516A CN201210141751A CN102631396B CN 102631396 B CN102631396 B CN 102631396B CN 2012101417516 A CN2012101417516 A CN 2012101417516A CN 201210141751 A CN201210141751 A CN 201210141751A CN 102631396 B CN102631396 B CN 102631396B
- Authority
- CN
- China
- Prior art keywords
- component
- ethanol
- total
- total alkaloids
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 95
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 81
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 35
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 7
- 239000002131 composite material Substances 0.000 title abstract 8
- 229930013930 alkaloid Natural products 0.000 claims abstract description 99
- 150000003648 triterpenes Chemical class 0.000 claims abstract description 95
- 239000000284 extract Substances 0.000 claims abstract description 30
- 239000002994 raw material Substances 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 276
- 239000000203 mixture Substances 0.000 claims description 72
- 238000010828 elution Methods 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 31
- 239000002904 solvent Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000011347 resin Substances 0.000 claims description 19
- 229920005989 resin Polymers 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 17
- 238000010992 reflux Methods 0.000 claims description 17
- 239000003480 eluent Substances 0.000 claims description 16
- 239000012535 impurity Substances 0.000 claims description 16
- 238000001291 vacuum drying Methods 0.000 claims description 15
- 241000512005 Alstonia Species 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 28
- 241000699670 Mus sp. Species 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 24
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract description 16
- 210000000952 spleen Anatomy 0.000 abstract description 11
- 210000001541 thymus gland Anatomy 0.000 abstract description 10
- 229960004397 cyclophosphamide Drugs 0.000 abstract description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 7
- 238000011740 C57BL/6 mouse Methods 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 4
- 102000015696 Interleukins Human genes 0.000 abstract 2
- 108010063738 Interleukins Proteins 0.000 abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 2
- 229940088592 immunologic factor Drugs 0.000 abstract 1
- 230000001875 tumorinhibitory effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 150000003797 alkaloid derivatives Chemical class 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 241000864415 Cornus controversa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000002481 ethanol extraction Methods 0.000 description 3
- AFJPGVUCVDCFPM-BBFZNYENSA-N methyl (1S,9R,10S,12S,13E,15S,18R)-13-ethylidene-10-hydroxy-18-(hydroxymethyl)-15-methyl-8-aza-15-azoniapentacyclo[10.5.1.01,9.02,7.09,15]octadeca-2,4,6-triene-18-carboxylate Chemical compound COC(=O)[C@]1(CO)[C@H]2C[C@H](O)[C@@]34Nc5ccccc5[C@@]13CC[N@@+]4(C)C\C2=C\C AFJPGVUCVDCFPM-BBFZNYENSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 240000005369 Alstonia scholaris Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- UBWVEGSADBOAEC-BASWHVEKSA-N Picrinine Natural products COC(=O)C1C2CC3C4Nc5ccccc5C14CCN3C/C/2=C/C UBWVEGSADBOAEC-BASWHVEKSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- BDXYPHKGNUGUFG-WAYFEFRKSA-N deacetyl-deformopicraline Natural products COC(=O)[C@@H]1[C@H]2C[C@@H]3N(CC2=CC)[C@@H]4C[C@]15c6ccccc6N[C@]35O4 BDXYPHKGNUGUFG-WAYFEFRKSA-N 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BDXYPHKGNUGUFG-VETGLWQVSA-N picrinine Chemical compound C12=CC=CC=C2N[C@]2(O3)[C@@H]4C[C@@H]5[C@@H](C(=O)OC)[C@]12C[C@H]3N4C\C5=C\C BDXYPHKGNUGUFG-VETGLWQVSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000012913 prioritisation Methods 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700161 Rattus rattus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Chemical compound C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 125000003523 triterpene group Chemical group 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an anti-lung cancer alstonia-leaf traditional Chinese herbal composite, a method for preparing the same and an application thereof in preparing an anti-lung cancer medicine. The raw material of the composite is traditional Chinese herbal alstonia-leaf. The composite consists of total alkaloids ingredient and total triterpenoids ingredient in alstonia-leaf extract; and the total alkaloids ingredient and the total triterpenoids ingredient are respectively mixed according to the mass ratio 1/0.1-1/10 of the crude dose of the raw material. The invention further provides the method for preparing the anti-lung cancer alstonia-leaf traditional Chinese herbal composite and the application of the anti-lung cancer alstonia-leaf traditional Chinese herbal composite in preparing the anti-lung cancer medicine. The anti-lung cancer alstonia-leaf traditional Chinese herbal composite has a good tumor inhibitory effect on C57BL/6 tumor-bearing mice, can obviously improve the immunity of the mice, compared with cyclophosphamide, the alstonia-leaf composite can obviously improve the immune factor (thymus index, spleen index and liver index) of the tumor-bearing mice and the interval cell factor (tumor necrosis factor (TNF)-a and interleukin (IL)-6) of the mice, thus having stronger anti-cancer activity, lower toxic and side effects, a safe and reliable curative effect, and being an effective anti-cancer medicine.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, be specifically related to a kind of Folium Alstoniae Scholaris Chinese medicine composition, its preparation method and application in preparing anti-lung-cancer medicament thereof of anti-pulmonary carcinoma.
Background technology
Under the many-side impact of the factors such as environmental pollution, occupational exposure, in world wide, the lung cancer morbidity rate continues to rise, and has become the malignant tumor to the human health risk maximum.Pulmonary carcinoma accounts for 17.8% of all tumor mortality in China city, in the Cancer Mortality sequence, has risen to first.According to China Health statistical yearbook result in 2010, show: Chinese city lung cancer mortality in 2009 is 49.6/10 ten thousand people, and the rural area lung cancer mortality is 39.64/10 ten thousand people, accounts for respectively 29.2% and 24.7% of tumor mortality number.At Urban Areas, every dead 4 people, namely have 1 people to die from cancer, and in the every 3-4 people who dies because of cancer, it is pulmonary carcinoma that 1 people is namely arranged.Pulmonary carcinoma still lacks medicine safely and efficiently at present, and patients with lung cancer prognosis and survival rate are all poor.Therefore it is very urgent and necessary researching and developing novel anti-lung-cancer medicament.
The vinblastine in natural plants source, happiness number alkali etc. have been developed to the effective antitumour medicine, and continuing from Chinese medicine and natural drug, finding and develop anti-lung-cancer medicament is current study hotspot.Cornus controversa
Alstonia scholaris (L.) R. Br., be the arbor of Apocynaceae Alstonia, mainly contain the compositions such as alkaloid, flavone, triterpenes, nature and flavor are sweet, light, flat, have the effects such as heat-clearing and toxic substances removing, reducing swelling and alleviating pain, antiasthmatic-antitussive, preventing the attack (or recurrence) of malaria, diaphoresis, stomach invigorating.Lamp-stand tree root, stem, skin, Ye Junke are used as medicine, take skin and leaf medication as main.In recent years, along with the progressively expansion to aspect researchs such as its chemical composition, pharmacologically actives, find that its active component is abundant, at aspects such as antitumor, antiinflammatory, antibiotic, anti-diabetic and blood fat reducing, demonstrate important potential medical value.Folium Alstoniae Scholaris is the dried leaves of Cornus controversa, and tradition is usually used in treating the diseases such as lung-heat, cough, abundant expectoration.Folium Alstoniae Scholaris mainly contains the compositions such as alkaloids, flavonoid, triterpenes.
Patent has been reported the preparation of Folium Alstoniae Scholaris treatment cough, asthma, pharyngitis, and (200710063724.0 disclose a kind of Chinese medicine composition for the treatment of cough, asthma; 201010171142.6 disclose a kind of medicine for the treatment of pharyngitis), about the patent of the anti-pulmonary carcinoma of Folium Alstoniae Scholaris, report is not arranged.
According to the literature, lamp-stand bark 85% ethanol extraction has good anti-tumor activity, from the opposed polarity solvent position that its separation obtains, insoluble position, total extract and chloroform extract to the cytotoxicity of HeLa cell after with dissolve with methanol are best, and these position alkaloids are abundant.(referring to Jagetia GC, Baliga MS.The effect of seasonal variation on the antineoplastic activity of Alstonia scholaris R.Br, in HeLa cells[J] .J Ethnopharmacol.2005, 96 (1-2): be 37-42.) one of main alkaloid composition of Cornus controversa from separating the ditaine (echitamine) that obtains Cornus controversa, it external to HeLa, HepG2, HL60, KB, MCF-7, Vero, fibrosarcoma and ehrlich ascites cell all have cytotoxicity, body is interior to the rat fibrosarcoma, S180 sarcoma and mice ehrlich ascites tumor have the effect that suppresses growth (referring to Jagetia GC, Baliga MS, Venkatesh P, et al.Evaluation of the cytotoxic effect of the monoterpene indole alkaloid echitamine in-vitro and in tumour-bearing mice[J] .J Pharm Pharmacol.2005, 57 (9): 1213-1219.).Folium Alstoniae Scholaris and lamp-stand bark, root are similar, also contain the compositions such as a large amount of similarly alkaloids, therefore from extraction Folium Alstoniae Scholaris, having the active component of anti-tumor activity and develop anti-lung-cancer medicament is a feasible approach, and is conducive to taking full advantage of and sustainable development of Cornus controversa resource.
But prior art, to the research from extracting antitumor drug Folium Alstoniae Scholaris or preliminary, not yet has the report of the concrete medicine that can realize industrialization, more have no from Folium Alstoniae Scholaris, extract specifically for the report of anti-lung-cancer medicament.
Summary of the invention
The purpose of this invention is to provide a kind of Folium Alstoniae Scholaris Chinese medicine composition, its preparation method and the application in preparing anti-lung-cancer medicament thereof of anti-pulmonary carcinoma, to realize the industrialization of anti-lung-cancer medicament.
The scheme that completes above-mentioned first invention task is: a kind of Folium Alstoniae Scholaris Chinese medicine composition of anti-pulmonary carcinoma, it is characterized in that, and the crude drug of said composition is the Chinese medicine Folium Alstoniae Scholaris.
Further optimize, the Folium Alstoniae Scholaris Chinese medicine composition of above-mentioned anti-pulmonary carcinoma is comprised of the total alkaloids component in alstonia and total triterpene component, and described total alkaloids component and total triterpene component are the mass ratio 1:0.1 ~ 1:10 combination by its raw material crude drug amount;
Be combined as preferably: two kinds of components are by its raw material crude drug amount mass ratio 1:0.5 ~ 1:5 combination;
Optimal being combined as: two kinds of components are by its raw material crude drug amount mass ratio 1:1 combination.
Wherein said total alkaloids component is take picrinine as representative composition; Described total triterpene component is take oleanolic acid and ursolic acid as representative composition.The accompanying drawing explanation is shown in by the HPLC collection of illustrative plates.
Folium Alstoniae Scholaris wherein, the nature and flavor hardship, cool, have cough-relieving, eliminate the phlegm, the effect of antiinflammatory.
More particularly, anti-pulmonary carcinoma Chinese medicine composition of the present invention refers to the compositions that obtains according to following preparation method:
Step (1): the Folium Alstoniae Scholaris alcohol reflux, reclaim solvent, obtain extracting concentrated solution;
Step (2): will extract on concentrated solution on macroporous resin, first water, low-concentration ethanol wash away impurity, then concentration ethanol eluting in using, and collect eluent, reclaim ethanol, obtain the total alkaloids component, finally use the high concentration ethanol eluting, collect eluent, reclaim ethanol, obtain total triterpene component, vacuum drying, obtain total alkaloids component and total triterpene component respectively;
Step (3): the total alkaloids component in step (2) and total triterpene combination of components are in the same place (mix homogeneously), obtain pharmaceutical composition of the present invention.
In step (3), the mass ratio 1:0.1 that total alkaloids component and total triterpene component are its raw material crude drug amounts ~ 1:10 combination; Portfolio ratio is preferably: by its raw material crude drug amount mass ratio 1:0.5 ~ 1:5 combination; Optimal portfolio ratio is: by its raw material crude drug amount mass ratio 1:1 combination.When the portfolio ratio of two kinds of components exceeds 1:1, can be with other crude drug, extract total alkaloids component or total triterpene component add in compositions.
The present invention adopts macroporous resin that the ethanol extraction of Folium Alstoniae Scholaris is separated into to different components, by experiment in vivo and vitro, its anti-lung cancer activity component is screened, obtaining Folium Alstoniae Scholaris anti-lung cancer activity component is total alkaloids and total triterpene component, and two components are made up, obtain the anti-pulmonary carcinoma compositions of Folium Alstoniae Scholaris.Such research is without report, and can carry out large-scale production, suitablely is developed to anti-pulmonary carcinoma new Chinese medicine.
The scheme that completes second invention task of the present invention is that the preparation method of the anti-pulmonary carcinoma Chinese medicine composition of above-mentioned Folium Alstoniae Scholaris, comprise the steps:
Step (1): the Folium Alstoniae Scholaris alcohol reflux, reclaim solvent, obtain extracting concentrated solution;
Step (2): will extract on concentrated solution on macroporous resin, first water, ethanol wash away impurity, then concentration ethanol eluting in using, and collect eluent, reclaim ethanol, obtain the total alkaloids component, finally use the high concentration ethanol eluting, collect eluent, reclaim ethanol, obtain total triterpene component, vacuum drying, obtain total alkaloids component and total triterpene component respectively;
Step (3): the total alkaloids component in step (2) and total triterpene combination of components are in the same place (mix homogeneously), obtain pharmaceutical composition of the present invention.
In step (3), the mass ratio 1:0.1 that total alkaloids component and total triterpene component are its raw material crude drug amounts ~ 1:10 combination; Portfolio ratio is preferably: by its raw material crude drug amount mass ratio 1:0.5 ~ 1:5 combination; Optimal portfolio ratio is: by its raw material crude drug amount mass ratio 1:1 combination.When the portfolio ratio of two kinds of components exceeds 1:1, can be with other crude drug, extract total alkaloids component or total triterpene component add in compositions.
The further optimization of above preparation method, concrete operation step is:
Step (1): Folium Alstoniae Scholaris is with percent by volume 70% ~ 95% alcohol reflux of 6 ~ 15 times of amounts 1 ~ 4 time, and each 1 ~ 4h, reclaim solvent, obtains extracting concentrated solution;
Step (2): will extract on concentrated solution on HPD400A, NKA-9, D101, DA201, AB-8 type macroporous resin, first use the water of 2 ~ 6BV and percent by volume 20% ~ 40% ethanol of 2 ~ 6BV to wash away impurity, use again percent by volume 50% ~ 65% ethanol elution of 4 ~ 10BV, collect eluent, reclaim ethanol, obtain the total alkaloids component, finally use percent by volume 70% ~ 95% ethanol elution of 4 ~ 10BV, collect eluent, reclaim ethanol, obtain total triterpene component, vacuum drying, obtain total alkaloids component and total triterpene component respectively;
Step (3): by the total alkaloids component in step (2) and total triterpene component mix homogeneously, obtain anti-pulmonary carcinoma Chinese medicine composition of the present invention.
The prioritization scheme of Chinese medicine composition preparation method of the present invention is:
Step (1): Folium Alstoniae Scholaris is with percent by volume 80% ~ 90% alcohol reflux of 8 ~ 12 times of amounts 1 ~ 3 time, and each 1.5 ~ 3h, reclaim solvent, obtains extracting concentrated solution;
Step (2): will extract on concentrated solution on D101, DA201, AB-8 type macroporous resin, first use the water of 3 ~ 5BV and percent by volume 30% ~ 40% ethanol of 3 ~ 5BV to wash away impurity, use again percent by volume 55% ~ 60% ethanol elution of 5 ~ 8BV, collect eluent, reclaim ethanol, obtain the total alkaloids component, finally use percent by volume 75% ~ 85% ethanol elution of 5 ~ 8BV, collect eluent, reclaim ethanol, obtain total triterpene component, vacuum drying, obtain total alkaloids component and total triterpene component respectively;
Step (3): by the total alkaloids component in step (2) and total triterpene component mix homogeneously, obtain anti-pulmonary carcinoma Chinese medicine composition of the present invention.
In the prioritization scheme of Chinese medicine composition preparation method, the condition that the present invention recommends is:
Step (1): Folium Alstoniae Scholaris is with percent by volume 85% alcohol reflux of 10 times of amounts 2 times, and each 2h, reclaim solvent, obtains extracting concentrated solution;
Step (2): will extract on concentrated solution on AB-8 type macroporous resin, first with the water of 4BV and percent by volume 40% ethanol of 4BV, wash away impurity, use again percent by volume 60% ethanol elution of 6BV, collected volume percentage ratio 60% ethanol elution, reclaim ethanol, obtain the total alkaloids component, finally use percent by volume 80% ethanol elution of 6BV, collected volume percentage ratio 80% ethanol elution, reclaim ethanol, obtain total triterpene component, vacuum drying, obtain total alkaloids component and total triterpene component respectively;
Step (3): by the total alkaloids component in step (2) and total triterpene component mix homogeneously, obtain anti-pulmonary carcinoma Chinese medicine composition of the present invention.
The scheme that completes the 3rd invention task of the present invention is, the application of anti-pulmonary carcinoma Chinese medicine composition in preparing anti-lung-cancer medicament of above-mentioned Folium Alstoniae Scholaris.
The prepared anti-lung-cancer medicament of compositions of the present invention is oral administration in use.
Can fill by mixing, the method for the routines such as tabletting prepares solid oral composition.
The data of alstonia pharmacological evaluation:
1. the preparation of different solvents extract
Get each 5 parts of 200 g Folium Alstoniae Scholarives, add respectively 10 times of amounts 85% ethanol, 70% ethanol, 50% ethanol, 30% ethanol, water reflux, extract,, (2 times, 2 h/ time), filtration, merging filtrate, reclaim respectively solvent, is concentrated into certain volume, 60 ℃ of drying under reduced pressure.Five solvent positions are designated as respectively DTY-85-T, DTY-70-T, DTY-50-T, DTY-30-T, DTY-W-T.Get different extract dried powders, weigh, calculate and extract yield, the results are shown in Table 1.
Table 1 Folium Alstoniae Scholaris medicinal substances extract result
| Extract part | Medical material weight (g) | Extract weight (g) | Yield (%) |
| DTY-85-T | 200 | 18.74 | 9.37 |
| DTY-70-T | 200 | 17.60 | 8.80 |
| DTY-50-T | 200 | 17.68 | 8.84 |
| DTY-30-T | 200 | 15.07 | 7.53 |
| DTY-W-T | 200 | 22.12 | 11.06 |
2. cell in vitro screening active ingredients
Cell strain: A549 and SPC-A-1 lung carcinoma cell
Take the logarithm trophophase A549, SPC-A-1 cell is made into respectively 6 * 10 with the RPMI-1640 culture fluid that contains 10% hyclone
4, 9 * 10
4Single cell suspension be inoculated in 96 orifice plates, every hole 100 μ L.Experimental group adds the culture medium that 90 μ L do not contain Ox blood serum, separately add Folium Alstoniae Scholaris medicinal liquid 10 μ L, make its final crude drug concentration be respectively 10 mg/mL, 5 mg/mL, 2.5 mg/mL, 1 mg/mL, positive controls adds cisplatin (1:10) 10 μ L, and it is 0.5%DMSO that the blank group adds 100 μ L final concentrations: ethanol (1:1) solution.Establish 6 parallel holes for every group, separately establish background control wells (equal-volume contains the acellular culture fluid of respective concentration medicine), be placed in 37 ℃ of 5%CO
2In incubator, cultivate 36 h, every hole adds MTT liquid 10 μ L, cultivate 4 h, discard the liquid in every hole, every hole adds DMSO 100 μ L, 10 min that vibrate are placed on 570 nm(and detect wavelength) and 630 nm(reference wavelengths) enzyme-linked immunosorbent assay instrument mensuration OD value, calculate inhibitory rate of cell growth (as follows), with SPSS 11.5 softwares, ask its half-inhibition concentration (IC
50).Above experiment repeats 3 times.
Inhibitory rate of cell growth=(matched group OD average-experimental group OD average)/matched group OD average * 100%
Table 2 A549 and SPC-A-1 cell drug effect evaluation result
"-" expression does not have activity
After administration 36h, DTY-85-T, DTY-70-T, the DTY-50-T IC to the A549 cell model
50Be respectively 275.48,327.36,371.28 μ g extract/mL, to the IC of SPC-A-1 cell model
50Be respectively 297.03,340.56,412.83 μ g extract/mL, the international standard 500 μ g extract/mL that all estimate less than Antitumor Activity of Drugs, the activity of the In Vitro Anti pulmonary carcinoma of the alstonia that wherein obtains with 85% ethanol extraction is best.
The effect of pharmaceutical composition in the present invention aspect anti-pulmonary carcinoma is below the data of compositions pharmacological evaluation:
1. on cellular level, screen active component
The preparation of cytoactive screen fraction: get Folium Alstoniae Scholaris medical material 5 kg, add 10 times of amount 85% alcohol reflux 2 times, each 2h, filter, and merging filtrate reclaims ethanol to extractum.By on extractum in the AB-8 macroporous resin, water, 10% ethanol, 20% ethanol, 30% ethanol, 40% ethanol, 50% ethanol, 60% ethanol, 70% ethanol, 80% ethanol, 95% ethanol carry out gradient elution successively, solvent is reclaimed respectively in these 10 eluting positions, 60 ℃ of drying under reduced pressure, obtain 10 elution fractions.Ten solvent compositions are designated as respectively DTY-water component, DTY-10% ethanol component, DTY-20% ethanol component, DTY-30% ethanol component, DTY-40% ethanol component, DTY-50% ethanol component, DTY-60% ethanol component, DTY-70% ethanol component, DTY-80% ethanol component, DTY-95% ethanol component.
The cytoactive screening
Cell strain: A549 and SPC-A-1 lung carcinoma cell
Take the logarithm trophophase A549, SPC-A-1 cell is made into respectively 6 * 10 with the RPMI-1640 culture fluid that contains 10% hyclone
4, 9 * 10
4Single cell suspension be inoculated in 96 orifice plates, every hole 100 μ L.Experimental group adds the culture medium that 90 μ L do not contain Ox blood serum, separately add Folium Alstoniae Scholaris medicinal liquid 10 μ L, make its final crude drug concentration be respectively 25 mg/mL, 12.5 mg/mL, 5 mg/mL, 2.5 mg/mL, positive controls adds cisplatin (1:10) 10 μ L, and it is 0.5%DMSO that the blank group adds 100 μ L final concentrations: ethanol (1:1) solution.Establish 6 parallel holes for every group, separately establish background control wells (equal-volume contains the acellular culture fluid of respective concentration medicine), be placed in 37 ℃ of 5%CO
2In incubator, cultivate 36 h, every hole adds MTT liquid 10 μ L, cultivate 4 h, discard the liquid in every hole, every hole adds DMSO 100 μ L, 10 min that vibrate detect wavelength in 570 nm() and 630 nm(reference wavelengths) wavelength enzyme-linked immunosorbent assay instrument mensuration OD value, calculate inhibitory rate of cell growth (as follows), with SPSS 11.5 softwares, ask its half-inhibition concentration (IC
50).Above experiment repeats 3 times.
Inhibitory rate of cell growth=(matched group OD average-experimental group OD average)/matched group OD average * 100%
Table 3 A549 and SPC-A-1 cell drug effect evaluation result
"-" expression can't be calculated IC
50
Experimental result shows that DTY-50% ethanol component, DTY-60% ethanol component, DTY-70% ethanol component, DTY-80% ethanol component and DTY-95% ethanol component have anti-lung cancer activity, but better with DTY-60% ethanol component, DTY-80% ethanol component anti-lung cancer activity, DTY-water component, DTY-10% ethanol component, DTY-20% ethanol component, DTY-30% ethanol component and DTY-40% ethanol component are without anti-lung cancer activity.
2. the anti-tumor in vivo of active component experiment
The preparation of anti-tumor in vivo experiment active component: by on 85% ethanol alstonia in the AB-8 macroporous resin adsorption, first with the water of 4BV and 40% ethanol of 4BV, wash away impurity, then use 60% ethanol elution of 6BV, obtain the total alkaloids component, finally use 80% ethanol elution of 6BV, obtain total triterpene component, measure two constituent contents, calculated purity, the results are shown in Table 4.Then these two active components of enrichment are carried out to the active checking of anti-tumor in vivo.
The result of table 4 total alkaloids and total triterpene enrichment
| Component | Solid yield/% | Content/% | Purity/% |
| Total alkaloids | 2.42 | 1.32 | 54.54 |
| Total triterpene | 1.19 | 0.78 | 65.54 |
The anti-tumor in vivo experiment
By a certain amount of Lewis murine lung cancer cell of In vitro culture, digest resuspended one-tenth single cell suspension, with sterilizing PBS, be prepared into cell suspension and regulate cell density to 1 * 10
7Individual/mL.Inoculation 0.2 mL cell suspension is subcutaneous in every right armpit of C57BL/6 mice rapidly.Weigh next day for the C57BL/6 black rat after inoculation Lewis cell, be divided at random normal saline negative control group, cyclophosphamide positive controls, prepare gained alkaloid component, triterpene component, alkaloid+triterpene component administration group.Press required dosage successive administration 14d respectively, the negative control group gavage gives normal saline, every day 0.4mL/ time; Positive controls is taked intraperitoneal injection of cyclophosphamide 20mg/kg/d; Alkaloid component, triterpene group, alkaloid component+triterpene component (waiting crude drug amount combination and compatibility) group dosage are: 15g crude drug/kg/d(high dose), 7.5g crude drug/kg/d(low dosage).The mice rear execution of weighing next day, get thymus, the spleen regulating liver-QI is weighed, and is calculated as follows thymus index, spleen index regulating liver-QI index.
Thymus index=thymic weight (mg)/Mouse Weight (g)
Spleen index=spleen weight (mg)/Mouse Weight (g)
Liver index=liver weight (mg)/Mouse Weight (g)
Tumour inhibiting rate (%)=(the average tumor weight of model group-average tumor weight of administration the group)/average tumor weight of model group * 100%
Table 5 pair Lewis tumor-bearing mice tumor control rate relatively
| Group | Body weight (g) | Tumor heavy (g) | Tumour inhibiting rate (%) |
| The normal saline group | 22.43±1.72 | 2.25±0.40 | ---- |
| The cyclophosphamide group | 20.26±2.54 | 0.90±0.20* | 60.00±8.89 |
| The total alkaloids high dose | 20.90±1.07 | 1.23±0.22* | 45.33±9.78 |
| The total alkaloids low dosage | 21.00±1.18 | 1.56±0.39* | 30.67±17.33 |
| Total triterpene high dose | 20.88±2.36 | 1.17±0.34* | 46.00±15.11 |
| Total triterpene low dosage | 20.43±1.72 | 1.43±0.35* | 36.44±15.56 |
| Total alkaloids+total triterpene high dose | 21.11±0.76 | 1.01±0.27* | 55.11±12.00 |
| Total alkaloids+total triterpene low dosage | 22.17±1.17 | 1.34±0.34* | 40.33±15.11 |
* be to compare (*, p<0.05**, p<0.01) with the normal saline group
As can be seen from Table 5, with the normal saline group, compare, total alkaloids component, total triterpene component, each administration group height dosed administration group of total alkaloids+total triterpene component heavily have significance to reduce to the tumor of Lewis lung cancer tumor-bearing mice, show that these several groups of medicines have significant Graft Versus Tumor to Lewis lung cancer.When component was individually dosed, alkaloid component, total triterpene component high dose group all showed stronger inhibitory action to the pulmonary carcinoma tumor-bearing mice, and tumour inhibiting rate is respectively 45.33%, 46.00%.After total alkaloids and total triterpene component compatibility, total alkaloids+total triterpene component all is better than independent component to pulmonary carcinoma tumor-bearing mice tumor suppression effect, inhibitory rate to 55.11%, the tumour inhibiting rate of the positive group of its suppression ratio and intraperitoneal injection of cyclophosphamide approaches, but because the present invention is natural drug, side effect obviously reduces.
Table 6 Lewis tumor-bearing mice thymus index, spleen index regulating liver-QI index are relatively
| Group | Thymus index (mg/g) | Spleen index (mg/g) | Liver index (mg/g) |
| The normal saline group | 1.67±0.27 + | 5.56±0.41 + | 54.13±7.34 + |
| The cyclophosphamide group | 1.45±0.20 * | 4.12±0.26 * | 43.35±3.59 * |
| The total alkaloids high dose | 1.84±0.31 *+ | 5.81±0.21* + | 61.41±3.61 *+ |
| The total alkaloids low dosage | 1.66±0.28 + | 5.52±0.22 + | 52.38±3.01 + |
| Total triterpene high dose | 1.85±0.20 *+ | 5.98±0.25 *+ | 64.35±3.34 *+ |
| Total triterpene low dosage | 1.69±0.25 + | 5.44±0.15 + | 53.95±3.23 + |
| Total alkaloids+total triterpene high dose | 2.01±0.30 *++ | 6.23±0.35 *++ | 67.99±3.48 *++ |
| Total alkaloids+total triterpene low dosage | 1.70±0.22 + | 5.44±0.21 + | 55.71±4.74 + |
* be to compare (*, p<0.05 with the normal saline group; *, p<0.01) ,+be with the cyclophosphamide group relatively (+, p<0.05; ++, p<0.01).
As can be seen from Table 6, with the normal saline group, compare, thymus index, the spleen index regulating liver-QI index of cyclophosphamide administration group mice have remarkable reduction, and may to be cyclophosphamide cause the inhibitory action of mouse immune system for this, and side effect is larger.With the cyclophosphamide group, compare, thymus index, the spleen index regulating liver-QI index of total alkaloids component, total triterpene component, total alkaloids+total triterpene component height dosed administration group mice have increase to a certain degree, wherein the thymus index of total alkaloids component and total triterpene component compatibility component administration group and spleen index have significance to increase, illustrate that total alkaloids component, total triterpene component all have the effect of certain enhancing immune function of mice, wherein the strongest with the effect that strengthens immune function of mice after alkaloid component and total triterpene component compatibility.
The mensuration of TNF-α and IL-6 in different dosing group mice plasma: measure according to the test kit recommend method.
In table 7 pair Lewis tumor-bearing mice blood plasma, TNF-a and IL-6 content are relatively
| Group | TNF-α concentration (pg/mL) | IL-6 concentration (pg/mL) |
| The normal saline group | 46.33±1.98 + | 34.56±3.76 + |
| The cyclophosphamide group | 40.35±2.36* | 28.44±4.59 * |
| The total alkaloids high dose | 49.57±2.93 *+ | 37.16±2.78 *+ |
| The total alkaloids low dosage | 46.04±2.36 + | 35.44±7.30 + |
| Total triterpene high dose | 48.39±1.15 *+ | 38.95±3.00 *+ |
| Total triterpene low dosage | 46.96±1.84 + | 36.81±7.94 + |
| Total alkaloids+total triterpene high dose | 51.70±1.42 *++ | 42.69±8.02 *++ |
| Total alkaloids+total triterpene low dosage | 47.49±4.46 + | 36.94±4.76 + |
" * " compares (*, p<0.05 with the normal saline group; *, p<0.01); "+" be with the cyclophosphamide group relatively (+, p<0.05; ++, p<0.01).
As can be seen from Table 7, with the normal saline group, compare, TNF-α and the IL-6 content of cyclophosphamide administration group have remarkable minimizing, and this may be to cause because of the inhibitory action of cyclophosphamide to the mouse immune system; With cyclophosphamide administration group, compare, TNF-α and the IL-6 content of total alkaloids component, total triterpene component, total alkaloids+total high low dosage of triterpene component all have significance to increase, wherein total alkaloids+total triterpene component high dose increase significantly (p<0.01).Illustrate that total alkaloids component, total triterpene component all have the effect of certain enhancing immune function of mice, wherein the strongest with the effect that strengthens immune function of mice after alkaloid component and total triterpene component compatibility.
3. the finger printing of active component
The finger printing of Folium Alstoniae Scholaris compositions is available from the C-18 reverse-phase HPLC system.
Alkaloidal chromatographic condition: chromatographic column Agilent ZORBAX Eclipse SB-C18 (4.6 mm * 250 mm, 5 μ m); Mobile phase A (acetonitrile), Mobile phase B (0.5% ammonia spirit), gradient elution: 0 ~ 5min, 20%A; 5 ~ 20min, 20%A ~ 40%A; 20 ~ 24min, 40%A; 24 ~ 25min, 40%A ~ 60%; 25 ~ 35min, 60%A.Flow velocity 1 mL/m in, 25 ℃ of column temperatures, detecting wavelength is 287 nm.Fig. 1 is shown in by the HPLC collection of illustrative plates
The chromatographic condition of triterpene: chromatographic column Agilent ZORBAX Eclipse SB-C18 (4.6 mm * 250 mm, 5 μ m); Mobile phase A (acetonitrile), Mobile phase B (phosphate buffer of pH7.6), gradient elution: 0 ~ 10min, 20%A; 11 ~ 15min, 80%A; 17 ~ 20min, 90%A.Flow velocity 1 mL/m in, 25 ℃ of column temperatures, detecting wavelength is 220 nm, Fig. 2 is shown in by the HPLC collection of illustrative plates.
Beneficial effect of the present invention: prepared Folium Alstoniae Scholaris compositions has good tumor-inhibiting action to the C57BL/6 tumor-bearing mice, can significantly improve the immunity of mice, with the cyclophosphamide group, compare, the Folium Alstoniae Scholaris compositions can significantly improve index of immunity (thymus index, spleen index regulating liver-QI index) and the Mice Body inner cell factor (TNF-a and IL-6) of tumor-bearing mice, therefore the Folium Alstoniae Scholaris compositions has stronger anti-lung cancer activity, lower toxic and side effects, curative effect is safe and reliable, is effective anti-lung-cancer medicament.
By the macroporous resin separating and purifying technology, obtain the active component of the anti-pulmonary carcinoma of Folium Alstoniae Scholaris, whole processing step is simple, and yield is high, and environmental friendliness can be carried out large-scale production, the suitable new Chinese medicine of preventing and treating pulmonary carcinoma that is developed to;
The present invention, in conjunction with modern preparation technique, can make the anti-pulmonary carcinoma compositions of Folium Alstoniae Scholaris in effective preparation of anti-pulmonary carcinoma, can be used as the medicine of clinical anti-pulmonary carcinoma.
The accompanying drawing explanation
Fig. 1: the HPLC collection of illustrative plates of compositions alkaloid component; 1-9 is unknown alkaloid component; 10 is picrinine.
Fig. 2: the HPLC collection of illustrative plates of compositions triterpene component.1-3,6-7 are unknown Triterpenoid; 4 is oleanolic acid; 5 is ursolic acid.
The specific embodiment
Pulverize compositions, add excipient, tabletting, make tablet.
Pulverize compositions, add conventional adjuvant, make pill.
Pulverize compositions, add the moist binding agent of ethanol, add starch to make filler, routine is pressed into granule.
Embodiment 4, and is substantially the same manner as Example 1, but following change is arranged: step (1): get the 1000g Folium Alstoniae Scholaris with 70% alcohol reflux of 15 times of amounts 1 time, each 4h, reclaim solvent, obtains extracting concentrated solution.Step (2): will extract on concentrated solution on D101 type macroporous resin, first with the water of 5BV and 40% ethanol of 5BV, wash away impurity, then use 60% ethanol elution of 8BV, collect 60% ethanol elution, reclaim ethanol, obtain the total alkaloids component, finally use 75% ethanol elution of 8BV, collect 75% ethanol elution, reclaim ethanol, obtain total triterpene component, vacuum drying, obtain total alkaloids and total triterpene component respectively.Step (3): the total alkaloids in step (2) and total triterpene component are pressed to crude drug amount 1:0.5 combination, obtain anti-pulmonary carcinoma Chinese medicine composition of the present invention.
Pulverize compositions, the conventional granulation, encapsulated.
Claims (7)
1. the Folium Alstoniae Scholaris Chinese medicine composition of an anti-pulmonary carcinoma, the crude drug of said composition is the Chinese medicine Folium Alstoniae Scholaris;
The Folium Alstoniae Scholaris Chinese medicine composition of described anti-pulmonary carcinoma is comprised of the total alkaloids component in alstonia and total triterpene component; Described total alkaloids component and total triterpene component are by the mass ratio 1:0.1 of its raw material crude drug amount ~ 1:10 combination;
It is characterized in that, the Folium Alstoniae Scholaris Chinese medicine composition of described anti-pulmonary carcinoma is the compositions for preparing in accordance with the following methods:
Step (1): the Folium Alstoniae Scholaris alcohol reflux, reclaim solvent, obtain extracting concentrated solution;
Step (2): will extract on concentrated solution on macroporous resin, first water, low-concentration ethanol wash away impurity, then concentration ethanol eluting in using, and collect eluent, reclaim ethanol, obtain the total alkaloids component, finally use the high concentration ethanol eluting, collect eluent, reclaim ethanol, obtain total triterpene component, vacuum drying, obtain total alkaloids component and total triterpene component respectively;
Step (3): by the total alkaloids component in step (2) and total triterpene component mix homogeneously, obtain pharmaceutical composition of the present invention;
Concrete operation step is:
Step (1): Folium Alstoniae Scholaris is with percent by volume 70% ~ 95% alcohol reflux of 6 ~ 15 times of amounts 1 ~ 4 time, and each 1 ~ 4h, reclaim solvent, obtains extracting concentrated solution;
Step (2): will extract on concentrated solution on HPD400A, NKA-9, D101, DA201, AB-8 type macroporous resin, first use the water of 2 ~ 6BV and percent by volume 20% ~ 40% ethanol of 2 ~ 6BV to wash away impurity, use again percent by volume 50% ~ 65% ethanol elution of 4 ~ 10BV, collect eluent, reclaim ethanol, obtain the total alkaloids component, finally use percent by volume 70% ~ 95% ethanol elution of 4 ~ 10BV, collect eluent, reclaim ethanol, obtain total triterpene component, vacuum drying, obtain total alkaloids component and total triterpene component respectively;
Step (3): by the total alkaloids component in step (2) and total triterpene component mix homogeneously, obtain anti-pulmonary carcinoma Chinese medicine composition.
2. the Folium Alstoniae Scholaris Chinese medicine composition of anti-pulmonary carcinoma according to claim 1, is characterized in that, described total alkaloids component and total triterpene component are by the mass ratio 1:0.5 of its raw material crude drug amount ~ 1:5 combination.
3. the Folium Alstoniae Scholaris Chinese medicine composition of anti-pulmonary carcinoma according to claim 2, is characterized in that, described total alkaloids component and total triterpene component are by the mass ratio 1:1 combination of its raw material crude drug amount.
4. the preparation method of the Folium Alstoniae Scholaris Chinese medicine composition of the described anti-pulmonary carcinoma of claim 1, is characterized in that, step is as follows:
Step (1): the Folium Alstoniae Scholaris alcohol reflux, reclaim solvent, obtain extracting concentrated solution;
Step (2): will extract on concentrated solution on macroporous resin, first water, low-concentration ethanol wash away impurity, then concentration ethanol eluting in using, and collect eluent, reclaim ethanol, obtain the total alkaloids component, finally use the high concentration ethanol eluting, collect eluent, reclaim ethanol, obtain total triterpene component, vacuum drying, obtain total alkaloids component and total triterpene component respectively;
Step (3): by the total alkaloids component in step (2) and total triterpene component mix homogeneously, obtain anti-pulmonary carcinoma Chinese medicine composition of the present invention;
Concrete operation step is:
Step (1): Folium Alstoniae Scholaris is with percent by volume 70% ~ 95% alcohol reflux of 6 ~ 15 times of amounts 1 ~ 4 time, and each 1 ~ 4h, reclaim solvent, obtains extracting concentrated solution;
Step (2): will extract on concentrated solution on HPD400A, NKA-9, D101, DA201, AB-8 type macroporous resin, first use the water of 2 ~ 6BV and percent by volume 20% ~ 40% ethanol of 2 ~ 6BV to wash away impurity, use again percent by volume 50% ~ 65% ethanol elution of 4 ~ 10BV, collect eluent, reclaim ethanol, obtain the total alkaloids component, finally use percent by volume 70% ~ 95% ethanol elution of 4 ~ 10BV, collect eluent, reclaim ethanol, obtain total triterpene component, vacuum drying, obtain total alkaloids component and total triterpene component respectively;
Step (3): by the total alkaloids component in step (2) and total triterpene component mix homogeneously, obtain anti-pulmonary carcinoma Chinese medicine composition of the present invention.
5. the preparation method of the Folium Alstoniae Scholaris Chinese medicine composition of anti-pulmonary carcinoma according to claim 4, it is characterized in that: the operating condition of step (1), (2) is:
Step (1): Folium Alstoniae Scholaris is with the alcohol reflux of the percent by volume 85% of 10 times of amounts 2 times, and each 2h, reclaim solvent, obtains extracting concentrated solution;
Step (2): will extract on concentrated solution on AB-8 type macroporous resin, first with the water of 4BV and percent by volume 40% ethanol of 4BV, wash away impurity, use again percent by volume 60% ethanol elution of 6BV, collected volume percentage ratio 60% ethanol elution, reclaim ethanol, obtain the total alkaloids component, finally use percent by volume 80% ethanol elution of 6BV, collected volume percentage ratio 80% ethanol elution, reclaim ethanol, obtain total triterpene component, vacuum drying, obtain total alkaloids component and total triterpene component respectively.
6. the application of Folium Alstoniae Scholaris Chinese medicine composition in preparing anti-lung-cancer medicament of anti-pulmonary carcinoma claimed in claim 1.
7. the application of Folium Alstoniae Scholaris Chinese medicine composition in preparing anti-lung-cancer medicament of anti-pulmonary carcinoma according to claim 6, is characterized in that, the prepared anti-lung-cancer medicament of described compositions is oral administration in use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101417516A CN102631396B (en) | 2012-05-07 | 2012-05-07 | Anti-lung cancer alstonia-leaf traditional Chinese herbal composite, method for preparing same and application thereof in preparing anti-lung cancer medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101417516A CN102631396B (en) | 2012-05-07 | 2012-05-07 | Anti-lung cancer alstonia-leaf traditional Chinese herbal composite, method for preparing same and application thereof in preparing anti-lung cancer medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102631396A CN102631396A (en) | 2012-08-15 |
| CN102631396B true CN102631396B (en) | 2013-11-20 |
Family
ID=46616076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101417516A Expired - Fee Related CN102631396B (en) | 2012-05-07 | 2012-05-07 | Anti-lung cancer alstonia-leaf traditional Chinese herbal composite, method for preparing same and application thereof in preparing anti-lung cancer medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102631396B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107693499A (en) * | 2017-10-13 | 2018-02-16 | 吉林化工学院 | A kind of preparation method of alstonia-leaf total flavones dispersible tablet |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100563670C (en) * | 2007-02-08 | 2009-12-02 | 中国药品生物制品检定所 | A kind of Chinese medicine composition for the treatment of cough, asthma |
-
2012
- 2012-05-07 CN CN2012101417516A patent/CN102631396B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 刘旋等.灯台树化学成分与药理活性研究进展.《中草药》.2012,第43卷(第3期),598－604页. |
| 灯台树化学成分与药理活性研究进展;刘旋等;《中草药》;20120331;第43卷(第3期);598－604页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102631396A (en) | 2012-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102600219B (en) | Total flavone extract of abelmoschus manihot and preparing method of total flavone extract | |
| CN101904968B (en) | Preparation method of Chinese paris rhizome yam type saponin and anti-tumor medicinal preparation thereof | |
| CN101554409B (en) | Long pepper alkaloid and preparation method, preparation and application thereof | |
| CN103007052A (en) | Compound dendrobium extract composition capable of delaying senility | |
| CN112472729B (en) | Application of caulis sinomenii in preparing medicine for treating human glioma | |
| CN104292353B (en) | A kind of antioxidation natural plant polyose and preparation method thereof | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN101628021A (en) | Preparation method of effective part of radix bupleuri and application thereof | |
| Zhang et al. | Quantitative evaluation of in vitro effects and interactions of active fractions in a Chinese medicinal formula (Yaotongning Capsule) on rat chondrocytes | |
| CN108434399B (en) | Traditional Chinese medicine composition for enhancing sensitivity of breast cancer chemotherapy and preparation method thereof | |
| CN102247479B (en) | Antitumor strong medicine and preparation method thereof | |
| CN1775267A (en) | Kaikoujian extract, Its preparing method and use | |
| CN101912514A (en) | Paris rhizome total saponin capsules with anti-tumor effect and preparation method thereof | |
| CN102631396B (en) | Anti-lung cancer alstonia-leaf traditional Chinese herbal composite, method for preparing same and application thereof in preparing anti-lung cancer medicine | |
| CN108159160B (en) | Combined medicine for treating colorectal cancer | |
| CN107446014A (en) | The Dulong Paris polyphylla ethanol extract and its application in pharmacy is separated with its chemical composition and authentication method | |
| CN103550718A (en) | Traditional Chinese medicine composition for treating lung cancer | |
| CN104095912B (en) | Treat the preparation method of the Chinese patent drug of rheumatism bone disease | |
| CN101371877B (en) | Qi tian dropping pill extract and Qi tian dropping pill as well as method for producing the same | |
| CN105535050A (en) | Radix angelica sinensis antitumor medicine | |
| CN1903308B (en) | Active position of Omithogalum caudatum ait, its preparation method, medicine and application thereof | |
| CN101040899B (en) | Antineoplastic Chinese traditional compound and the preparation and the method for producing the same | |
| CN101081240A (en) | Medicinal composition of oxymatrine and polysaccharide | |
| CN103223066A (en) | Chinese medicinal extract | |
| CN103230456A (en) | Traditional Chinese medicine extract and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131120 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |